Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus NORLUTIN.
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs NORLUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium. Ethinyl estradiol is an estrogen that provides cycle control and contributes to contraceptive efficacy. Ferrous fumarate provides iron supplementation.
Synthetic progestin that binds to progesterone receptors, suppressing gonadotropin secretion and altering endometrial lining.
One tablet (1 mg norethindrone acetate, 20 mcg ethinyl estradiol, and 75 mg ferrous fumarate) orally once daily for 28 days, without interruption. Take the first tablet on the first day of menstrual bleeding.
5 mg orally three times daily for endometriosis; 5 mg orally daily from day 5 to day 25 of menstrual cycle for amenorrhea.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal). Ethinyl estradiol: 10-20 hours (terminal). Clinical context: Steady-state achieved after 5-7 days; half-life supports once-daily dosing.
Terminal elimination half-life: 5–14 hours (mean ~8 hours). Clinical context: short half-life necessitates daily dosing for contraceptive efficacy.
Norethindrone acetate and ethinyl estradiol are primarily excreted in urine (40-60% as metabolites) and feces (20-40% as metabolites). Ferrous fumarate is absorbed and iron is utilized; unabsorbed iron is excreted in feces.
Mainly renal as glucuronide and sulfate conjugates; approximately 70% renal, 30% fecal/biliary.
Category D/X
Category C
Progestin
Progestin